Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer.
Saved in:
| Title: | Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. |
|---|---|
| Authors: | Roudko V; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Del Valle DM; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Radkevich E; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kelly G; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Hui X; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Patel M; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gonzalez-Kozlova E; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Tuballes K; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA., Atale S; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Wang L; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., CzinCzin B; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Kim-Schulze S; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Wistuba II; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Al-Atrash G; Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Manyam G; Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang J; Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, UK., Thompson R; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Suarez-Farinas M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Lheureux S; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Gnjatic S; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA sacha.gnjatic@mssm.edu.; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Feb 25; Vol. 13 (2). Date of Electronic Publication: 2025 Feb 25. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
